• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Federal watchdog to investigate CMS drug rebate program

December 12, 2016 By Sarah Faulkner

Federal watchdog to investigate CMS drug rebate programThe Office of the Inspector General of the Health and Human Services Departments said last week that it will begin investigating whether the Centers for Medicare & Medicaid Services properly monitors its Medicaid Drug Rebate Program. The investigation comes after CMS reported that Mylan (NSDQ:MYL) underpaid Medicaid by not paying appropriate rebates. The Canonsburg, Penn.-based company said it would pay $465 million to settle the claims with the Justice Department, but the federal government has not confirmed such a deal.

The federal watchdog’s office will also investigate whether other pharmaceutical companies have complied with the drug rebate policies or have similarly underpaid Medicaid.

Companies pay rebates to CMS in exchange for Medicaid coverage and the rebates are lower for generic products. Companies pay 13% for generics, compared to 23% for a brand-name product. Mylan classified its EpiPen emergency allergy device as a generic, but CMS reported that it “has, on multiple occasions, provided guidance to the industry and Mylan on the proper classification of drugs and has expressly told Mylan that the product is incorrectly classified.”

CMS also said that once companies are warned that their products are improperly classified, it is then the company’s responsibility to reclassify the device or drug. But some lawmakers are concerned that without proper oversight, companies could take advantage of the discrepancy, potentially costing taxpayers millions of dollars.

Last week, Inspector General Dan Levinson wrote to Sen. Chuck Grassley (R-Iowa), chair of the Senate Judiciary Committee, and said that his agency will look at the rebate data reported by companies, the process by which manufacturers determine rebates and how CMS prevents inappropriate payments for unapproved drugs.

“HHS OIG shares the concerns expressed … regarding CMS’s oversight of the Medicaid Drug Rebate Program to ensure the correct classification of drugs, including EpiPen, and address the potential consequences to State Medicaid programs and beneficiaries,” Levinson wrote.

“The more we learn about the misclassifications, the more we know this program is in dire need of proper oversight,” Grassley said in a statement. “It’s unclear whether CMS took any action between 2009 and now to get the EpiPen classification back on track after being told about the misclassification. If CMS did nothing, that’s a dereliction of duty to the taxpayers. The OIG is right to look at this program and help determine whether it works or doesn’t work as intended.”

Filed Under: Featured, Legal News, Pharmaceuticals, Policy, Wall Street Beat Tagged With: Capitol Hill, Centers for Medicare and Medicaid Services (CMS), Mylan

IN CASE YOU MISSED IT

  • Tandem Diabetes Care wins CE mark for Mobi insulin pump with Control-IQ+ technology
  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott
  • Study links Abbott CGM use to lower risk of hospitalizations due to heart complications

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS